Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
Completed · Phase 3
Conditions studied: Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis, Blastomycosis, Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis, Invasive Pulmonary Aspergillosis, Recurrent Vulvovaginal Candidiasis, Other Emerging Fungi
In brief
This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.
Key facts
- Study ID
- NCT03059992
- Run by
- Scynexis, Inc.
- People needed
- 233
- Starts
- 2017-04-01
- Expected to finish
- 2023-08-25
- Last updated by the study team
- 2024-11-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Alabama at Birmingham — Birmingham, Alabama, United States
- UC Davis Medical Center — Sacramento, California, United States
- University of California San Francisco — San Francisco, California, United States
- Emory University Hospital Midtown — Atlanta, Georgia, United States
- Augusta University — Augusta, Georgia, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- University of Michigan — Ann Arbor, Michigan, United States
- Wayne State University — Detroit, Michigan, United States
- University of Minnesota — Minneapolis, Minnesota, United States
- Mayo Clinic — Rochester, Minnesota, United States
- Washington University School of Medicine — St Louis, Missouri, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- Weill Cornell Medical College — New York, New York, United States
- Stony Brook University Medical Center — Stony Brook, New York, United States
- Duke University Medical Center — Durham, North Carolina, United States
- Wake Forest Baptist Medical Center — Winston-Salem, North Carolina, United States
- University of Pittsburg Medical Center — Pittsburgh, Pennsylvania, United States
- University of Texas Southwestern Medical Center Dallas — Dallas, Texas, United States
- University of Texas Health Science Center at Houston — Houston, Texas, United States
- University of Wisconsin — Madison, Wisconsin, United States
- Medical University of Graz Department of Internal Medicine, Department of Pulmology, Section for Infectious Disease and Tropical Medicine — Graz, Austria
- Medical University Innsbruck — Innsbruck, Austria
- Universitätsklinikum Köln, Klinik I für Innere Medizin — Cologne, Germany
- Universitätsklinikum Essen, Klinik für Infektiologie — Essen, Germany
- Universitätsklinikum Frankfurt, Department of Internal Medicine II — Frankfurt, Germany
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.